Compare TG Therapeutics Inc (TGTX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs DENTSPLY SIRONA Inc — how do they compare? TG Therapeutics Inc trades at $54.8 (market cap $8.16B), while DENTSPLY SIRONA Inc trades at $8.76 (market cap $1.73B). The key difference: TG Therapeutics Inc is far larger — about 4.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| TGTX | XRAY | |
|---|---|---|
Market Cap | $8.16B | $1.73B |
Volume | 1,735,121 | 6,198,582 |
Sector | Health | Health |
52-Week High | $59.06 | $14.68 |
52-Week Low | $26.94 | $8.52 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $8.37B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Dentsply Sirona (XRAY) trades at $8.73, near its 52-week low, with a bearish technical signal and negative profitability metrics. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid a challenging dental market environment.
The outlook remains cautious due to persistent margin pressure and sales declines, though the consensus price target of $13.40 suggests potential upside. Key risks include competitive pressures and execution of the turnaround plan, while institutional buying indicates some long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
